Emerging Modalities in DMPK

Next-generation small molecule medicines like PROTACs offer potential solutions for previously untreatable diseases, and accurately measuring their DMPK properties is crucial for drug discovery and development. Due to their long half-lives and low systemic concentrations, high-sensitivity bioanalysis is essential.

Waters UPLC-MS/MS and advanced chromatography solutions, sample preparation kits, standards, and high-sensitivity mass spectrometry systems simplify method development and ensure high-quality quantitative bioanalysis assays across modality types—supporting the evolution of safe and effective medicines.